Page 175 Acute Pain Management
P. 175




Safety
studies
and
widespread
clinical
experience
with
morphine,
fentanyl
and
sufentanil
have

shown
no
neurotoxicity
or
behavioural
changes
at
normal
clinical
intrathecal
doses
(Hodgson
et

al,
1999
Level
IV).
Other
opioid
agonists
or
partial
agonists
do
not
have
animal
or
human

safety
data.


Early
clinical
studies
used
very
high
intrathecal
morphine
doses
(ie
500
mcg
or
more),
however

adequate
postoperative
analgesia
with
fewer
adverse
effects
may
be
obtained
with

significantly
less
morphine
—
although
at
lower
doses
there
is
not
a
clear
dose‐response

relationship
for
some
side
effects
or
pain
relief
(Meylan
et
al,
2009
Level
I).
A
meta‐analysis

comparing
intrathecal
morphine
doses
of
less
than
300
mcg,
equal
to
or
greater
than
300
mcg,

and
placebo
reported
a
greater
risk
of
respiratory
depression
and
of
nausea
and
vomiting
with

the
higher,
but
not
lower,
doses
of
morphine,
while
the
incidence
of
pruritus
was
increased
for

all
doses
(Gehling
&
Tryba,
2009
Level
I).


Following
hip
and
knee
arthroplasty,
intrathecal
morphine
(100
to
300
mcg)
provided
excellent

analgesia
for
24
hours
after
surgery
with
no
difference
in
side
effects;
after
hip
arthroplasty

only
there
was
a
significant
reduction
in
postoperative
patient‐controlled
(PCA)
morphine

requirements
(Rathmell
et
al,
2003
Level
II).
Following
knee
arthroplasty,
intrathecal
morphine

500
mcg
compared
with
200
mcg
reduced
supplemental
rescue
analgesia
(tramadol)
over

24
hours
with
no
difference
in
adverse
event
rates
(Bowrey
et
al,
2005
Level
II),
and
200
mcg
was

as
effective
as
300
mcg
with
no
difference
in
side
effects;
both
were
superior
to
100
mcg

(Hassett
et
al,
2008
Level
II).
After
hip
arthroplasty,
100
mcg
and
200
mcg
doses
of
intrathecal

morphine
produced
good
and
comparable
pain
relief
and
reductions
in
postoperative

morphine
requirements;
50
mcg
was
ineffective
(Murphy
et
al,
2003
Level
II).


When
combined
with
low‐dose
bupivacaine
for
Caesarean
section,
100
mcg
intrathecal

morphine
produced
analgesia
comparable
with
doses
as
high
as
400
mcg,
with
significantly
 CHAPTER
5

less
pruritus
(Girgin
et
al,
2008
Level
II).
A
single
dose
of
morphine
(100
mcg)
added
to
a
spinal

anaesthetic
for
Caesarean
section
prolonged
the
time
to
first
postoperative
analgesic

administration
resulting
in
at
least
11
hours
of
effective
analgesia.
Adverse
effects
included

pruritus
(43%),
nausea
(10%)
and
vomiting
(12%).
The
rate
of
respiratory
depression
was
low

(see
below).
In
these
patients,
sufentanil
and
fentanyl
showed
no
analgesic
benefits
(Dahl
et
al,

1999
Level
I).


The
addition
of
10
mcg
sufentanil
to
0.4
mg
intrathecal
morphine
did
not
potentiate

postoperative
analgesia
or
reduce
intraoperative
opioid
requirements
in
patients
undergoing

major
colorectal
surgery
(Culebras
et
al,
2007
Level
II).
The
addition
of
intrathecal
fentanyl
to

low‐dose
spinal
bupivacaine
for
anorectal
surgery
resulted
in
more
pruritus
but
lower
mean

recovery
and
discharge
times,
with
fewer
analgesic
requests
in
the
fentanyl
group
(Gurbet
et
al,

2008
Level
II).

In
a
more
recent
study,
intrathecal
sufentanil
provided
shorter
postoperative
analgesia
(mean

6.3
hours)
than
intrathecal
morphine
(mean
19.5
hours)
with
no
difference
in
side
effects

(Karaman
et
al,
2006
Level
II).
In
another
comparison
of
intrathecal
morphine
(100
mcg)
and

intrathecal
pethidine
(10
mg)
for
analgesia
following
Caesarean
section
in
a
non‐blinded
study,

patients
receiving
morphine
had
longer
analgesia
and
fewer
intraoperative
side
effects
than

the
pethidine
group,
but
experienced
more
pruritus
(Kumar
et
al,
2007
Level
II).

For
more
information
on
effectiveness
and
side
effects
related
to
the
use
of
intrathecal

opioids
see
Section
7.3.









 Acute
pain
management:
scientific
evidence
 127

   170   171   172   173   174   175   176   177   178   179   180